SCHEMBL14564656

SCHEMBL14564656

CC(C)Cc1nnc(-c2ccc3[nH]nc(-c4ccc5c(c4)OCC5)c3c2)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.41
MAP2K4 P45985 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
MAPKAPK3 Q16644 1/20 0.41
MAPK6 Q16659 1/20 0.41
MAPKAPK5 Q8IW41 1/20 0.41
CDC7 O00311 1/20 0.39
PLK4 O00444 1/20 0.39
DCLK1 O15075 1/20 0.39
MAPK13 O15264 1/20 0.39
DAPK3 O43293 1/20 0.39
DYRK3 O43781 1/20 0.39
JAK2 O60674 1/20 0.39
ROCK2 O75116 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
NTRK1 P04629 1/20 0.39
CDK1 P06493 1/20 0.39
RET P07949 1/20 0.39
ROS1 P08922 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5389304 0.85 CSNK1D (0.43) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL5384000 0.77 CSNK1D (0.43) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL5375974 0.73 MAP2K4 (0.50) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL5394830 0.73 MAPK8 (0.48) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL5378377 0.71 CSNK1D (0.44) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL5378004 0.69 MAP2K4 (0.58) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6
SCHEMBL14564655 0.68 MAPK8 (0.44) MAP2K4CDC7DYRK3JAK2ROCK2
SCHEMBL4093932 0.67 HRH3 (0.40) DYRK3JAK2PRKD3MAP4K4TYK2
SCHEMBL4093940 0.67 HRH3 (0.40) DYRK3JAK2PRKD3MAP4K4TYK2
SCHEMBL8286311 0.66 MAPK1 (0.43) MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds SIGNAL PHARMACEUTICALS, LLC 2007-03-15 US disclosed
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds SIGNAL PHARMACEUTICALS, LLC 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060616-A1 Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds BCL9, MCL1, INMT MAPK1 2816/4885MAP2K4 3021/4885MAPKAPK2 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.